Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Status:
Completed
Trial end date:
2004-11-12
Target enrollment:
Participant gender:
Summary
1. To assess the treatment related mortality of allogeneic stem cell transplantation with
non-myeloablative therapy incorporating the lymphodepleting MAb CAMPATH-1H, in patients
with hematological diseases and renal cell carcinoma not eligible for conventional
(myeloablative) therapy.
2. To assess the time to engraftment and incidence of graft failure in patients receiving
this transplant regimen.
3. To assess the safety, pharmacokinetics and immunologic activity of CAMPATH-1H when used
as part of a subablative conditioning regimen.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital The Methodist Hospital Research Institute The Methodist Hospital System